AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2847994
Drug: Oral delta‐9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC), 15 mg/m2
Trial: 2847994
Drug: Prochlorperazine (PCZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (PCZ), 10 mg
Trial: 31670603
Drug: Naringenin 150
RxNorm normalized name: NARINGENIN
DrugBank: Naringenin (DB03467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringenin 150 mg from an extract of whole oranges standardized to 28% naringenin, taken three times/day for 8 weeks
Trial: 31301434
Drug: SRP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP and irrigation with CUR solution (100 mg/L)
Trial: 31301434
Drug: SRP, irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP, irrigation with CUR solution (100 mg/L), and LED irradiation (465-485 nm, 60 s)
Trial: 26615377
Drug: Midazolam 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.01 mg/kg/IV and ketamine 1 mg/kg/IV
Trial: 11166906
Drug: vCP205 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 vaccine
Trial: 11522187
Drug: vCP205 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 vaccine with SF-2 rgp120
Trial: 9573498
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy with lisinopril
Trial: 9573498
Drug: Low-dose therapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose therapy with lisinopril
Trial: 9573498
Drug: Medication use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use variation
Trial: 3408038
Drug: Diltiazem (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (loading dose 0.5 mg.kg‐1 followed by infusion of 5 micrograms.kg‐1.min‐1)
Trial: 30433862
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg oral BH4 (BH4-5)
Trial: 30433862
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg oral BH4 (BH4-20)
Trial: 26438119
Drug: mDCF (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDCF (fluorouracil 2,000 mg/m2 IV over 48 hours, docetaxel 40 mg/m2 IV on day 1, cisplatin 40 mg/m2 IV on day 3, every 2 weeks)
Trial: 26438119
Drug: DCF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony‐stimulating factor, every 3 weeks)
Trial: 23039034
Drug: Lopinavir/Ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (LPV/r) 40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg
Trial: 23039034
Drug: Lamivudine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 7.5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg
Trial: 19874149
Drug: Visual impairment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual impairment, self‐reported poor vision, dependence in daily activities, cognitive impairment, depressive symptoms, female gender, older age
Trial: 17700042
Drug: S 17092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 17092 (100, 200, 400 or 600 mg)
Trial: 23088748
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin therapy
Trial: 23088748
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin therapy
Trial: 406561
Drug: Intramuscular insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular insulin therapy
Trial: 30443924
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence to HTN treatment
Trial: 30443924
Drug: Poor adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor adherence to HTN treatment
Trial: 25821405
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 μg/kg administered 30 seconds before induction
Trial: 23445184
Drug: Caregiver-mediated medication
RxNorm normalized name: carbinoxamine maleate Oral Solution [Pediatex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver-mediated medication management
Trial: 21388549
Drug: Enteral rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral rosuvastatin administered once daily for 14 days
Trial: 21388549
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered once daily for 14 days
Trial: 19270824
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin
Trial: 17355494
Drug: Thioctic acid
RxNorm normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioctic acid 600 mg p.o./day
Trial: 12765890
Drug: parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib 40 mg i.v.
Trial: 17257175
Drug: ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg i.v.
Trial: 26607392
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (800 μg/day for 16 weeks)
Trial: 22294059
Drug: Lercanidipine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine administered in the fasted state
Trial: 22294059
Drug: Lercanidipine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine administered 15 min before a standard breakfast
Trial: 10587334
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of lisinopril (32.5 to 35 mg daily)
Trial: 10587334
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of lisinopril (2.5 to 5.0 mg daily)
Trial: 9193426
Drug: High ACE
RxNorm normalized name: HIGH ACETATE MULTIPLE ELECTROLYTE ADDITIVE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ACE activity (> 12 IU/L)
Trial: 9193426
Drug: Low ACE
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low ACE activity (<= IU/L)
Trial: 1554040
Drug: Progesterone suppository
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone suppository treatment
Trial: 2861874
Drug: Intramuscular pipothiazine
RxNorm normalized name: pipothiazine
DrugBank: Pipotiazine (DB01621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pipothiazine palmitate (PP)
Trial: 24764147
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Pantoprazole
Trial: 24764147
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Rabeprazole
Trial: 11278152
Drug: Medicated schizophrenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated schizophrenic patients during initial assessment after receiving medication
Trial: 11278152
Drug: Medicated schizophrenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated schizophrenic patients after sustained treatment
Trial: 11278152
Drug: First-episode schizophrenic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-episode schizophrenic patients (medication-naïve or not)
Trial: 30149417
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once a day for 12 weeks
Trial: 30037778
Drug: Donepezil 5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5-10 mg daily
Trial: 26540028
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/d) for 12 months
Trial: 21051191
Drug: modified Constraint‐Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified Constraint‐Induced Movement Therapy followed by Bimanual Training (mCIMT‐BiT)
Trial: 18484473
Drug: Carbapenem monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem monotherapy (imipenem or meropenem)
Trial: 17139586
Drug: Short-acting insulin
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting insulin analogs
Trial: 17139586
Drug: Meta-analyses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analyses of short-acting insulin analogs
Trial: 11783322
Drug: Longshoudan (LSD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longshoudan (LSD) treatment for 4 weeks
Trial: 3479839
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug period
Trial: 3479839
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (NSAID) or analgesic trials
Trial: 31857431
Drug: Adavosertib (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (110 mg/m2) with Irinotecan (90 mg/m2)
Trial: 31857431
Drug: Adavosertib (85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (85 mg/m2) with Irinotecan (90 mg/m2)
Trial: 25796155
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo capsule (control)
Trial: 23782950
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (100 μg once daily for 24 to 30 months)
Trial: 23782950
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with anti‐thyroid drugs
Trial: 21112881
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene ropivacaine 0.2% 2 ml h⁻¹ with mandatory 6 hourly boluses
Trial: 21112881
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene ropivacaine 0.2% 5 ml h⁻¹ with PRN boluses
Trial: 15491239
Drug: Paroxetine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine CR 12.5 mg
Trial: 15491239
Drug: Paroxetine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine CR 25 mg
Trial: 14704300
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (160 mg of ferrous sulfate, 50 mg elemental iron, twice daily; total of 320 mg ferrous sulfate, 100 mg elemental iron daily)
Trial: 2424341
Drug: Prophylactic corticosteroid
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic corticosteroid and/or antihistamine pretreatment
Trial: 18227177
Drug: Vancomycin >=4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin >=4 g/day
Trial: 18227177
Drug: Vancomycin <4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin <4 g/day
Trial: 1932300
Drug: Standard IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IVIG (Sandoglobulin, 0.1 mg/kg IgM)
Trial: 1932300
Drug: IgM-enriched IVIG
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched IVIG (Pentaglobin, 30 mg/kg IgM)
Trial: 19411614
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug treatment (exact drug not specified)
Trial: 15658650
Drug: Decoction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction of Qingre Huoxue recipe (QHR) given one dose per day in addition to standard treatment.
Trial: 15658650
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including impact therapy of methyl-prednisolone followed by oral prednisone, with additional cyclophosphamide or mycophenolate mofetil for some patients.
Trial: 9021434
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen (400 mg)
Trial: 8206111
Drug: Pyridostigmine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine, 120 mg p.o.
Trial: 8206111
Drug: Pyridostigmine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine, 120 mg p.o. (GHRH stimulated)
Trial: 3382764
Drug: Tamoxifen at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen at a dose of 10 mg twice daily
Trial: 30467695
Drug: Niaoduqing Particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaoduqing Particles (5 g thrice daily and 10 g before bedtime for 24 weeks)
Trial: 30467695
Drug: Niaoduqing Particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaoduqing Particles (after open-label treatment)
Trial: 28460246
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (COPE)
Trial: 25857594
Drug: Tratinterol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tratinterol hydrochloride tablets
Trial: 25857594
Drug: Procaterol hydrochloride
RxNorm normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol hydrochloride tablets (control)
Trial: 21649522
Drug: Bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepotastine besilate ophthalmic solution 1.5%
Trial: 21649522
Drug: Bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepotastine besilate ophthalmic solution 1.0%
Trial: 7812991
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg oral clomipramine daily
Trial: 7812991
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oral clomipramine daily
Trial: 65126
Drug: Immune serum
RxNorm normalized name: IMMUNE SERUMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune serum globulin (20 ml)
Trial: 31567325
Drug: Intrathecal Drug
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal Drug Delivery Systems (IDDS)
Trial: 23234632
Drug: Denosumab (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (180 mg subcutaneous every 4 weeks)
Trial: 23234632
Drug: Denosumab (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (180 mg subcutaneous every 12 weeks)
Trial: 15539971
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors and beta blockers
Trial: 15539971
Drug: Aldosterone blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone blocking agents
Trial: 9646192
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 240 mg twice daily
Trial: 9646192
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 120 mg nightly
Trial: 9646192
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg nightly
Trial: 3612896
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (10 g as SuperCharR suspension) administered 2 hr prior, and at 0, 2, 6, and 8 hr after tobramycin administration.
Trial: 3612896
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no activated charcoal treatment).
Trial: 23213069
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg
Trial: 28685495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin combined with 10 mg metformin (T1)
Trial: 28685495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin combined with 50 mg metformin (T2)
Trial: 28685495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin combined with 500 mg metformin (T3)
Trial: 28685495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin combined with 1 mg furosemide (T4)
Trial: 28685495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin combined with 5 mg furosemide (T5)
Trial: 27782861
Drug: Acupuncture (eight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (eight pragmatic Traditional Chinese Medicine treatments over 4 weeks)
Trial: 10199862
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 microgram/day)
Trial: 12870680
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Therapy (DOT)
Trial: 25624387
Drug: 0.2‐0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2‐0.5 mg/kg oral morphine
Trial: 25624387
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of oral ibuprofen
Trial: 21677052
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose (HF) - 80 g fructose/d
Trial: 21677052
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose (HS) - 80 g sucrose/d
Trial: 21677052
Drug: Medium fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium fructose (MF) - 40 g fructose/d
Trial: 21677052
Drug: Medium glucose
RxNorm normalized name: Medium glucose concentration peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium glucose (MG) - 40 g glucose/d
Trial: 21677052
Drug: High glucose
RxNorm normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glucose (HG) - 80 g glucose/d
Trial: 19434759
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of bronchial arterial infusion (BAI) and rAd‐p53
Trial: 14747675
Drug: H(2)-reduced (58)Fe
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas
Trial: 14747675
Drug: H(2)-reduced (58)Fe
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas plus Na(2)EDTA at a ratio of 1:2 mol/mol
Trial: 10966700
Drug: 1.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL/kg
Trial: 10966700
Drug: 2.0 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mL/kg
Trial: 10966700
Drug: 2.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL/kg
Trial: 10966700
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 100 mL
Trial: 6370975
Drug: Nomifensine (100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (100‐200 mg/day)
Trial: 11090260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplements)
Trial: 23216674
Drug: IFNβ‐1a, 44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ‐1a, 44 μg subcutaneously three times weekly (tiw)
Trial: 23216674
Drug: IFNβ‐1b, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ‐1b, 250 μg subcutaneously every other day
Trial: 18070305
Drug: Tilt training
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt training (daily sessions for three months)
Trial: 16250265
Drug: Fluvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin therapy for 12 weeks
Trial: 12020980
Drug: Lipid-lowering fibrate
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering fibrate (gemfibrozil 600 mg orally twice daily for 3 months, then combined with HRT for 6 months)
Trial: 12020980
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (2 mg oestradiol + 1 mg norethisterone acetate once daily for 3 months, then combined with gemfibrozil for 6 months)